(Q33402747)

English

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase III clinical trial

0 references

Adaptive radiation therapy

0 references

0 references

0 references

1 reference

based on heuristic

inferred from title

Annika Malmström

object named as

Annika Malmström

1

0 references

Ufuk M Abacioglu

object named as

Ufuk Abacioglu

7

0 references

object named as

Monika E Hegi

10

0 references

5

object named as

Didier Frappaz

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Bjørn Henning Grønberg

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Christine Marosi

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Roger Stupp

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Henrik Schultz

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Björn Tavelin

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Benoit Lhermitte

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Johan Rosell

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Roger Henriksson

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Nordic Clinical Brain Tumour Study Group (NCBTSG)

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

8 August 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

916-926

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970265-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970265-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970265-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970265-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970265-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970265-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970265-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970265-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with concomitant temozolomide.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970265-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970265-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970265-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970265-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Hypofractionated radiotherapy as palliative treatment in poor prognosis patients with high grade glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970265-6

7 January 2021

based on heuristic

inferred from DOI database lookup

A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970265-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970265-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The 2007 WHO classification of tumours of the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970265-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970265-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Tissue microarrays for high-throughput molecular profiling of tumor specimens

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970265-6

7 January 2021

based on heuristic

inferred from DOI database lookup

An agarose matrix facilitates sectioning of tissue microarray blocks

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970265-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970265-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Radiotherapy for glioblastoma in the elderly.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970265-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970265-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970265-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970265-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970265-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970265-6

7 January 2021

based on heuristic

inferred from DOI database lookup

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970265-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(12)70265-6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33402747&oldid=1898850900"